Qureight

Investor: Molten Ventures

Cambridge-based MedTech company Qureight has successfully closed an oversubscribed Series B funding round, securing £15 million ($20 million) in investment. The round was led by Molten Ventures and saw participation from existing investors including Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension.Summary of transaction details:Value: £15 million ($20 million)Sector: Healthcare & BiotechAdvisor: Not mentionedKey Entities: Qureight (Target), Molten Ventures (Lead Investor), Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, Ascension (Participating Investors)Location: Cambridge, UK (Target company)Note: This capital infusion will be instrumental in expanding Qureight's 3D deep-learning imaging portfolio, establishing a new AI imaging lab, and accelerating commercial growth into key new therapeutic markets for lung and heart diseases, further solidifying its leadership in the lung and heart imaging CRO market.

Investor: Molten Ventures

Qureight, a Cambridge-based health tech company, has secured $20m (£15m) in Series B funding to expand its AI-powered clinical trial imaging platform. Summary of transaction details: Value: $20m (£15m) Sector: Healthcare & Biotech Advisor: Not disclosed Key Entities: Qureight, Molten Ventures Location: Cambridge, UK Note: The funding will enable Qureight to construct a specialised AI imaging laboratory and expand its imaging CRO services beyond its core footprint in lung fibrosis into adjacent therapeutic areas, underscoring the potential of AI to accelerate discovery and transform clinical research.

Investor: Playfair Capital, Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Cambridge Angels, Meltwind, Ascension Life Fund

Investor: Meltwind, Ascension Ventures, Playfair Capital, Cambridge Angels